抗病毒药物市场规模、份额和成长分析（按适应症、患者类型、产品类型、药物类型、最终用户、分销管道和地区）- 产业预测，2025-2032 年

2023 年抗病毒药物市场规模价值 380 亿美元，预计将从 2024 年的 393.3 亿美元成长到 2032 年的 517.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 3.5%。

受爱滋病毒/爱滋病、B肝、C肝和流感等病毒感染疾病发病率上升的推动，全球抗病毒药物市场预计将大幅成长。需求激增促使製药公司大力投资研发，重点关注有望提高疗效、减少副作用和提高患者依从性的创新抗病毒疗法。新药物标靶的发现正在扩大治疗选择，同时对病毒感染的认识的提高凸显了早期疗育的重要性。此外，政府的支持措施和研究经费也进一步推动了市场的成长。公私合营部门合作正在改善药品的取得管道，而对临床试验的大量投资正在解决尚未满足的医疗需求并使市场走上不断扩大的轨道。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

抗病毒药物市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概况
• 流感
• 人类免疫力缺乏病毒（HIV）
• C型肝炎病毒
• 单纯疱疹病毒
• 巨细胞病毒(HCMV)
• 水痘带状疱疹病毒 (VZV)
• B型肝炎病毒
• 呼吸道融合病毒（RSV）
• 冠状病毒感染
• 其他的

抗病毒药物市场规模（按患者类型和复合年增长率） (2025-2032)

• 市场概况
• 孩子
• 成人
• 年龄较大

抗病毒药物市场规模（按产品类型和复合年增长率） (2025-2032)

• 市场概况
• 口服
• 外用
• 肠外

抗病毒药物市场规模（按药物类型和复合年增长率） (2025-2032)

• 市场概况
• 非专利的
• 品牌

抗病毒药物市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院
• 诊所
• 家庭医疗保健
• 专业中心
• 门诊中心
• 其他的

抗病毒药物市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 网路药局
• 零售药局

抗病毒药物市场规模（按地区划分）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Gilead Sciences Inc.（USA）
• AbbVie, Inc.（USA）
• GlaxoSmithKline（UK）
• Merck& CO, Inc.（USA）
• Janssen Pharmaceuticals, Inc.（USA）
• Bristol-Meyrs Squibb Company（USA）
• Mylan NV（Netherlands）
• Novartis AG（Switzerland）
• AstraZeneca（UK）
• Pfizer Inc.（USA）
• Cipla Inc.（India）
• Johnson & Johnson Services, Inc.（USA）
• Aurobindo Pharma（India）
• Merck MRK（USA）
• Reddy Laboratories Limited（India）
• Hoffmann-La Roche Ltd.（Switzerland）
• Altesa Biosciences Inc.（USA）
• Sanofi（France）
• Eli Lilly（USA）
• Roche（Switzerland）

结论和建议

Antiviral Drugs Market size was valued at USD 38.0 billion in 2023 and is poised to grow from USD 39.33 billion in 2024 to USD 51.79 billion by 2032, growing at a CAGR of 3.5% during the forecast period (2025-2032).

The global antiviral drugs market is poised for considerable growth, driven by rising incidence rates of viral infections such as HIV/AIDS, hepatitis B and C, and influenza. This surge in demand has prompted pharmaceutical companies to invest heavily in research and development, focusing on innovative antiviral therapies that promise increased efficacy, fewer side effects, and better patient compliance. The discovery of new drug targets has widened treatment options, while heightened awareness around viral infections has underscored the importance of early intervention. Additionally, supportive government initiatives and funding for research have further propelled market growth. Collaborative efforts within public-private partnerships are enhancing drug accessibility, while significant investments in clinical trials are addressing unmet medical needs, solidifying the market's expansion trajectory.

Top-down and bottom-up approaches were used to estimate and validate the size of the Antiviral Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Antiviral Drugs Market Segments Analysis

Global Antiviral Drugs Market is segmented by Indication, Patient Type, Products, Drug Type, End User, Distribution Channel and Region. Based on Indication, the market is segmented into Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus, Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus, Respiratory Syncytial Virus, Coronavirus Infection and Others. Based on Patient Type, the market is segmented into Child, Adult and Geriatric. Based on Products, the market is segmented into Oral, Topical and Parenteral. Based on Drug Type, the market is segmented into Generic and Branded. Based on End User, the market is segmented into Hospital, Clinics, Home Healthcare, Speciality Centers, Ambulatory Centers and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Antiviral Drugs Market

The widespread incidence of HIV/AIDS has significantly heightened the demand for antiretroviral therapies, thereby propelling the growth of the antiviral drugs market. The advent of highly active antiretroviral therapy (HAART) has transformed the treatment landscape for HIV/AIDS, providing effective management solutions that enhance the quality of life and extend the life expectancy of those affected by the virus. This progress not only underscores the critical need for innovative antiviral drugs but also fuels investment and research in this sector, further catalyzing market expansion as healthcare providers strive to offer comprehensive care for individuals living with HIV/AIDS.

Restraints in the Antiviral Drugs Market

The antiviral drugs market faces significant restraints primarily due to the stringent and time-consuming regulatory approval processes. Manufacturers encounter challenges in meeting demanding safety, efficacy, and quality standards, which can result in considerable delays for the market entry of new antiviral treatments. Such strict regulations not only complicate the approval landscape but can also impede the timely availability of crucial therapies. Adhering to these rigorous regulatory frameworks is essential for ensuring drug safety and effectiveness, yet this compliance can substantially elongate the timelines for both development and approval, ultimately impacting the accessibility of vital antiviral medications for patients in need.

Market Trends of the Antiviral Drugs Market

The antiviral drugs market is currently witnessing a significant shift towards the development of broad-spectrum antiviral medications, reflecting a growing need for effective treatments against a variety of emerging viral infections. This trend is fueled by the limitations of traditional antiviral drug development, which often targets specific strains or types of viruses. Broad-spectrum antivirals present advantages such as cost-effectiveness, rapid responsiveness to outbreaks, and enhanced patient outcomes through their capability to combat multiple viral pathogens simultaneously. Innovations in drug discovery, including the exploration of viral host factors and diverse antiviral mechanisms, are further propelling this market trend, positioning broad-spectrum antivirals as a cornerstone in future antiviral therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Antiviral Drugs Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Influenza
• Human Immunodeficiency Virus (HIV)
• Hepatitis C Virus
• Herpes Simplex Virus
• Human Cytomegalovirus (HCMV)
• Varicella-Zoster Virus (VZV)
• Hepatitis B Virus
• Respiratory Syncytial Virus
• Coronavirus Infection
• Others

Global Antiviral Drugs Market Size by Patient Type & CAGR (2025-2032)

• Market Overview
• Child
• Adult
• Geriatric

Global Antiviral Drugs Market Size by Products & CAGR (2025-2032)

• Market Overview
• Oral
• Topical
• Parenteral

Global Antiviral Drugs Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Generic
• Branded

Global Antiviral Drugs Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital
• Clinics
• Home Healthcare
• Speciality Centers
• Ambulatory Centers
• Others

Global Antiviral Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Antiviral Drugs Market Size & CAGR (2025-2032)

• North America (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Gilead Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck& C.O., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Meyrs Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N. V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck MRK (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reddy Laboratories Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Altesa Biosciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations